Chinese Pharmas Develop Generic Of GSK’s Relenza
This article was originally published in PharmAsia News
A pair of Chinese pharmaceutical companies and a team of scientists report success in developing a way to produce Relenza (zanamivir) locally for treating avian influenza. U.K.-based GlaxoSmithKline had licensed the drug to Materia Medica and Nanjing Effact Pharm Drug Development, but did not supply the technology, relying on them to reproduce the drug. The China-made version has received permission to undergo clinical trials. Roche, which makes the rival bird flu drug Tamiflu (oseltamivir), has granted licenses to two other Chinese pharmas to make generics. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.